Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

2021354 citationsJournal Articlehybrid Open Access

Authors

D. Ross Camidge · University of Colorado Denver

Hye Ryun Kim · Yonsei University

Myung‐Ju Ahn · Samsung Medical Center

James Chih‐Hsin Yang · National Taiwan University

Ji‐Youn Han · National Cancer Center

Maximilian J. Hochmair

Ki Hyeong Lee · Chungbuk National University Hospital

Abstract

In the ALTA-1L final analysis, with longer follow-up, brigatinib continued to exhibit superior efficacy and tolerability versus crizotinib in patients with or without poor prognostic biomarkers. The suggested survival benefit with brigatinib in patients with brain metastases warrants future study.

Topics & Keywords

Lung Cancer Treatments and Mutations Lung Cancer Research Studies Cancer therapeutics and mechanisms

Publication Details

Published in: Journal of Thoracic Oncology

Volume 16, Issue 12, pp. 2091-2108

DOI: 10.1016/j.jtho.2021.07.035

Field-Weighted Citation Impact: 36.99

Command Palette

Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

Authors

Abstract

Topics & Keywords

Publication Details